Filing Flows › Comparisons › CODX vs OBIO
Co-Diagnostics vs Orchestra BioMed Holdings: CODX and OBIO compared
Co-Diagnostics is the larger company: $166K of revenue in its latest quarter (Q2 2026) against $88K for Orchestra BioMed Holdings (Q2 2026). Co-Diagnostics is growing faster (+2% against -90% a year earlier).
Where the money goes: CODX and OBIO
Co-Diagnostics (CODX) · Q2 2026
Co-Diagnostics, Q2 2026: revenue $166K (+2% year over year), net loss $6.3M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Orchestra BioMed Holdings (OBIO) · Q2 2026
Orchestra BioMed Holdings, Q2 2026: revenue $88K (-90% year over year), net loss $23.8M, operating cash flow −$19.3M. The chart follows the revenue to costs, profit and cash.
| Co-Diagnostics (CODX) | Orchestra BioMed Holdings (OBIO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $166K | $88K |
| Revenue growth, Y/Y | +2% | -90% |
| Operating margin | n/m | n/m |
| Net earnings | −$6.3M | −$23.8M |
| Operating cash flow | −$7.2M | −$19.3M |
Questions
Which is bigger, Co-Diagnostics or Orchestra BioMed Holdings?
Co-Diagnostics is the larger company: $166K of revenue in its latest quarter (Q2 2026) against $88K for Orchestra BioMed Holdings (Q2 2026).
Is Co-Diagnostics or Orchestra BioMed Holdings growing faster?
Co-Diagnostics is growing faster (+2% against -90% a year earlier).
More: Co-Diagnostics earnings · how Co-Diagnostics makes money · Orchestra BioMed Holdings earnings · how Orchestra BioMed Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 10, 2026). Fiscal quarters can end on different dates. Not investment advice.